Why did llyra drop so from 3.85

The drop in LYRA's stock price from $3.85 to $0.30 can be attributed to the company's disappointing clinical trial results for its potential treatment of chronic rhinosinusitis. The Phase 3 trial of LYR-210 did not meet its primary endpoint of "statistically significant improvement" compared to the sham control, leading to a failure to improve three major symptoms of chronic rhinosinusitis. This setback likely affected investor confidence and contributed to the significant decline in LYRA's stock price.